Skip to main content
Trending storyContinuously updated

Sofinnova Partners closes €725M Crossover II fund

1 reports1 report sources16 hours agoUpdate

Get up to speed on this story

AI Summary

Paris-based life sciences VC Sofinnova Partners closed its second crossover fund at €725 million, above its original target, the firm announced Nov. 16. Sofinnova Crossover II plans to invest in about 15 companies, mainly in Europe with selective US and international deals. It has already backed Hemab Therapeutics, CellCentric and Neurent Medical. The fund is backed by the European Tech Champions Initiative, a fund of funds managed by the European Investment Fund.

AI-generated from reports · 15 hours agoUpdate

Report timeline

Follow the reports to understand different sides of the story.

Nov 16
  1. Tech Funding NewsTop Deals
    Sofinnova Partners closes €725M Crossover II fund for European life sciences

    Sofinnova Partners closed its second crossover fund at €725 million, above its original target.

Trend for this story

Comparable range current
7
Comparable range peak
10Nov 16 20:00
Change in the last 24 hours
–

Trends only compare the same entities observed consistently and completely, so the scope may be smaller than the current trending statistics. Move the pointer or click the chart to view hourly trending; use the left and right arrow keys on a keyboard to switch.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing